Nivolumab (Opdivo) for gastric and gastroesophageal junction adenocarcinoma – third and fourth line
NIHR HSRIC
Record ID 32016001003
English
Authors' objectives:
Nivolumab is a new drug to treat advanced stomach cancer. It is delivered straight into the blood via a drip. Nivolumab may help the body's immune system to fight the disease. Stomach cancer is an unusual type of cancer, and gastric and gastroesophageal junction adenocarcinoma are the most common types of stomach cancer. Nivolumab may offer a new treatment option for people whose cancer has returned following previous treatments.
Details
Project Status:
Completed
URL for project:
http://www.hsric.nihr.ac.uk/topics/nivolumab-opdivo-for-gastric-and-gastroesophageal-junction-adenocarcinoma/
Year Published:
2016
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Adenocarcinoma
- Esophageal Neoplasms
- Esophagogastric Junction
- Nivolumab
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.